Fresenius Kabi AG Announces Launch of Oxaliplatin Injection, USP

Published: Aug 09, 2012

SCHAUMBURG, Ill.--(BUSINESS WIRE) -- Fresenius Kabi today announced that is has launched Oxaliplatin Injection, USP. Oxaliplatin Injection, USP, is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin, and indicated for adjuvant therapy of stage III colon cancer in patients who have undergone complete resection of the primary tumor as well as for the treatment of advanced colorectal cancer.

Back to news